A new review article has just been published in the journal Critical Reviews in Hematology Oncology. It is probably a current “must read” for support group leaders and for any patients who are interested in the idea of using immunotherapy as a treatment for progressive and advanced forms of prostate cancer.
The full text of this article by Maia and Hansen, entitled “A comprehensive review of immunotherapies in prostate cancer“, is accessible on line. The basic premise of the article is that most completed trials of immunotherapeutics in the treatment of advanced prostate cancer (to date) have contained inherent flaws because of the ways that the developers were rushing to bring their products to market. We are still waiting to see whether the Phase III trial of Prostvac-VF has overcome those problems … and hopefully we will hear later this year.
Filed under: Management, Treatment | Tagged: immunotherapy, review |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply